A Multicenter, Follow-up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects with Relapsed and Refractory Multiple Myeloma

A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer

A Phase III, open-label, randomized Study of MPDL3280A (Anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma

BMS CA209-498 – A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma

Phase I/II-Studie zu MK-3475 (Pembrolizumab) bei Kindern mit fortgeschrittenem Melanom oder einem PD-L1 positiven fortgeschrittenen, rezidivierten oder therapierefraktären solidem Tumor oder Lymphom, bei der die Pharmakokinetik, Pharmakodynamik, Toxizität, Sicherheit und antitumorale Aktivität von MK-3475 untersucht werden

Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer

SIMPLIFY – A Multicenter, Open-Label Immunogenicity and Safety Study of subcutaneous Natalizumab 300 mg administered to Subjects with Relapsing Multiple Sclerosis

Talimogene Laherparepvec T-VEC 20110265

A Phase Ib/II, open-label, multicenter study of INC280 in combination with buparlisib in adult patients with recurrent glioblastoma

A phase II, multicenter, three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease

A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma

A randomised, double blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in newly diagnosed patients with inoperable locally advanced NSCLC after definitive concurrent chemoradiation therapy

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE-119)

ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK- 3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group

An Open-Label, Multicenter, Phase 1 Study of Ramucirumab plus Pembrolizumab in Patients with Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium

Studie MK-3475 -185